MDXH (MDxHealth) Float Percentage Of Total Shares Outstanding: 75.49% (As of Jul. 04, 2026)


MDXH MDxHealth SA MDXH
45 GF Score
Price $0.48
GF Value $2.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth Float Percentage Of Total Shares Outstanding?

MDxHealth MDXH -6.26% 45 Float Percentage Of Total Shares Outstanding is 75.49% as of Jul. 04, 2026. GuruFocus rates MDXH with a GF Score™ of 45/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MDxHealth's float shares is 38.77 Mil. MDxHealth's total shares outstanding is 51.36 Mil. MDxHealth's float percentage of total shares outstanding is 75.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MDxHealth's Insider Ownership is 0.19%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MDxHealth's Institutional Ownership is 48.18%.

MDXH
45GF Score
MDxHealth SA MDXH
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MDxHealth Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MDxHealth's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=38.77/51.36
=75.49%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 75.49% mean?
MDxHealth (MDXH) has a Float Percentage Of Total Shares Outstanding of 75.49% as of Jul. 04, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MDxHealth and its competitors.
Is MDxHealth's Float Percentage Of Total Shares Outstanding too high?
MDxHealth's current Float Percentage Of Total Shares Outstanding is 75.49%. Overall, MDxHealth has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Float Percentage Of Total Shares Outstanding compare to AWHL and BIOQ?
MDxHealth's Float Percentage Of Total Shares Outstanding of 75.49% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Diagnostics & Research company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Diagnostics & Research industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MDxHealth and its competitors. MDxHealth's current Float Percentage Of Total Shares Outstanding is 75.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.48 — trading 78% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 75.49%. MDxHealth's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For MDxHealth (MDXH), the current Float Percentage Of Total Shares Outstanding is 75.49% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (MDXH) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of $0.48 is trading 78% below its estimated GF Value™ of $2.20. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for MDXH:

  • Float Percentage Of Total Shares Outstanding: 75.49%
  • GF Value™: $2.20 vs. price of $0.48 (78% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges O6C1:Germany
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score

Get the complete analysis for MDXH

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$2.20
GF Value